Crohn's disease - Induction of remission in patients with mild to moderate active Crohn's disease affecting the ileum and/or the ascending colon. Microscopic colitis - Induction of remission in patients with active microscopic colitis Maintenance of remission in patients with microscopic colitis.
AstraZeneca announced that it has entered into an agreement with Tillotts Pharma AG , part of the Zeria Group, for...
Ulcerative colitis involving rectal and recto-sigmoid disease.
AstraZeneca has announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights...
Cortiment is indicated in adults for: • induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient. • induction of remission in patients with active microscopic colitis (MC).